HMOX1 and non-small cell lung carcinoma: Cisplatin can promote the activation of the antioxidant system Nrf2/HO-1, while ginkgetin can inhibit the antioxidant system Nrf2/HO-1, and the combination of the two can promote the anti-tumor effect of cisplatin in non-small cell lung cancer cells (97).